KKKwang Min Kim

Kwang Min Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kwang Min Kim has a total of 91 co-authors. Here are the top co-authors by number of shared publications:

  • Byung Soo Kwan

    Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon 51353, Republic of Korea

    5 shared publications
  • Jun Ho Ji

    11Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of South Korea

    3 shared publications
  • Bo Ram Sung

    Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea

    2 shared publications
  • Eui-Suk Sung

    Department of Otorhinolaryngology – Head and Neck Surgery, College of Medicine, Pusan National University and Biomedical Research Institute, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea

    2 shared publications
  • Gi Cheol Park

    Department of Otolaryngology—Head and Neck Surgery, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon 51353, Republic of Korea

    2 shared publications
  • Hanaro Park

    Department of Otorhinolaryngology-Head & Neck Surgery, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon 51353, Republic of Korea

    2 shared publications

Latest Publications

  • Open Access

    Sex-divergent metabolic pathways in the association between vitamin D status and metabolic-associated fatty liver disease

    by Kwang Min Kim, Mi Hyeon Jin, Jeong-Hyun Yoon

    Vitamin D insufficiency has been linked to metabolic-associated fatty liver disease (MAFLD), but whether biological sex shapes this relationship remains poorly characterized. Building on a primary report that established this association in the pooled cohort, we tested whether the association and its candidate metabolic pathways differ by sex and, using age as a proxy for estrogen exposure, whether the association in women varies across the adult life course to clarify pathophysiological differences and therapeutic implications between men and women. In this cross-sectional secondary analysis, we analyzed 22,476 Korean adults with metabolic dysfunction (16,320 men and 6156 women). Sex-stratified multivariable logistic regression estimated the association between vitamin D insufficiency (P = .001) than in men (OR: 1.32, 95% CI: 1.22–1.43, P < .001). Insulin resistance was the predominant statistical mediator in both sexes but contributed more in women (58.6% vs 42.3% in men), whereas systemic inflammation was a significant mediator only in women (19.3%), and lipid metabolism and adiposity were more prominent in men. When age was used as an estrogen proxy, the association in women was numerically strongest in the youngest reproductive-age stratum and attenuated at older ages, although the vitamin D-by-age interaction was not statistically significant. Among women with high-risk alcohol consumption, the point estimate was higher (OR: 4.37, 95% CI: 1.79–10.67, P = .001), although this stratum was small (n = 308) and the estimate imprecise. Vitamin D insufficiency is associated with MAFLD in both sexes, but more strongly in women, and the candidate metabolic pathways differ between the sexes. These observations suggest that sex-specific strategies – targeting insulin sensitivity and inflammation in women and lipid metabolism and weight in men – may merit evaluation for MAFLD prevention and management. Because the design is cross-sectional, these associations are hypothesis-generating and require longitudinal confirmation.

  • Open Access

    Evaluating long-term outcomes of direct-acting antiviral therapy in chronic hepatitis C: A retrospective study

    by Bo Ram Sung, Sang Goon Shim, Kwang Min Kim, Jung Won Lee, Jun Young Kim, Bo Kyeong Lee, Cheon Hoo Jun, Byung Soo Kwan

    Direct-acting antiviral (DAA) therapy is now the recommended standard for chronic hepatitis C (CHC), demonstrating remarkable efficacy. Nonetheless, there is a relative lack of information concerning the sustained, long-term consequences of DAA treatment. Therefore, this study sought to investigate the long-term impact of DAA therapy on patients with CHC. We conducted a retrospective review of CHC patients who received DAA therapy at Samsung Changwon Hospital. Patients with preexisting hepatocellular carcinoma (HCC) and those lost to follow-up were excluded. Demographic, clinical, and virological data were analyzed, focusing on DAA treatment outcomes, liver fibrosis, and the relationship with HCC development. A total of 223 patients were included: 59.5% with CHC genotype 1, 93.3% treatment-naïve, and 26.5% with liver cirrhosis (LC). Treatment included asunaprevir and daclatasvir in 46.2%, with 46.2% receiving a 12-week regimen. Sustained virological response at 12 weeks (SVR12) was achieved in 97.8%, with 5 treatment failures. Post-treatment, APRI scores < 0.7 increased (68.2% vs 87.7%, P < .001), as did FIB-4 scores < 3.25 (60.1% vs 80.3%, P < .001). During follow-up, 9 patients developed HCC, with serum sodium identified as a risk factor (odds ratio: 0.6; confidence interval: 0.41–0.88; P = .008). DAA treatment effectively treats CHC and reduces liver fibrosis. However, further research is warranted to better understand and predict the development of HCC.


  • Open Access

    Synergistic impact of serum uric acid and ferritin on MAFLD risk: A comprehensive cohort analysis

    by Miyeong Bae, Kwang Min Kim, Mi Hyeon Jin, Jeong-Hyun Yoon

    The characterization of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) underscores metabolic anomalies as critical in fatty liver disease progression. Serum uric acid is increasingly recognized as a determinant for fatty liver diseases due to its association with metabolic disorders. Ferritin, in parallel, serves as an inflammatory marker closely tied to metabolic syndrome and insulin resistance. Our study explores the combined influence of serum uric acid and ferritin on MAFLD prevalence. We conducted a retrospective cohort analysis at Samsung Changwon Hospital’s Health Screening Center (2011–2018), encompassing 7,818 individuals post-exclusion criteria. Participants were stratified into gender-specific quartiles based on serum uric acid and ferritin levels. Utilizing multivariable Cox proportional hazard models alongside Kaplan-Meier analysis, we assessed the incidence of MAFLD and its relationship with these serum biomarkers, also performing subgroup assessments by gender, age, and BMI. Over 41,819 person-years with an average observation period of 5.35 ± 2.06 years, 1,073 incident cases of MAFLD were recorded. The risk of MAFLD was notably higher within the upper quartiles of serum uric acid (HR: 2.17, 95% CI: 1.70–2.78). Each increment in natural logarithmic serum uric acid level correlated with an increased risk (HR: 3.65, 95% CI: 2.32–5.74). Serum ferritin also indicated an enhanced risk, albeit less pronounced. The simultaneous presence of elevated levels of both uric acid and ferritin correlated with the highest MAFLD risk (HR: 3.89, 95% CI: 2.41–6.28). Our findings affirm that high serum uric acid levels significantly escalate the risk of MAFLD, with serum ferritin levels contributing to a lesser yet substantial degree. The concurrent elevation of both biomarkers magnifies MAFLD risk, reinforcing the need for their combined assessment in MAFLD risk evaluation.


  • Open Access

    Two Cases of Pancreatobiliary Disease Complications Treated Using Over-the-Scope Clip

    by Byung Soo Kwan, Bo Ram Sung, Kwang Min Kim

    The over-the-scope clip (OTSC) system is a powerful full-thickness suturing device used for closing refractory bleeding, perforations, and fistulas in gastrointestinal diseases, offering greater force than conventional clips. Here, we report two cases of pancreatobiliary disease treated using OTSC. The first case involved the successful OTSC ligation of a colonic fistula caused by necrotizing pancreatitis, and the second was a duodenal perforation due to stent migration, which was also successfully treated with OTSC. These cases indicate that OTSC can be beneficial for pancreatobiliary diseases, potentially eliminating the need for surgery when endoscopic treatment is successful.

  • Open Access

    Inhibiting Ferroptosis Prevents the Progression of Steatotic Liver Disease in Obese Mice

    by Gi Cheol Park, Soo-Young Bang, Ji Min Kim, Sung-Chan Shin, Yong-Il Cheon, Kwang Min Kim, Hanaro Park, Eui-Suk Sung, Minhyung Lee, Jin-Choon Lee, et al.

    Ferroptosis, a form of regulated cell death characterized by lipid peroxidation and iron accumulation, has been implicated in the progression of metabolic-dysfunction-associated steatohepatitis (MASH) in obesity. This study investigated the role of ferroptosis in the development of hepatic steatosis and MASH in obese mice and assessed the therapeutic potential of ferrostatin-1, a ferroptosis inhibitor. C57BL/6J wild-type (n = 8) and ob/ob mice (n = 16) were maintained on a standard chow diet. Mice were divided into three groups that included C57BL/6 (n = 8), ob/ob (n = 8), and ob/ob + ferrostatin-1 (FER) (n = 8), with the latter group receiving an intraperitoneal injection of 5 μM/kg ferrostatin three times per week for eight weeks. Following treatment, serum and tissue samples were collected for analysis. Significant hepatic steatosis and increased lipogenesis markers were observed in ob/ob mice, which were restored to baseline levels in the ob/ob + FER group treated with ferrostatin-1. Elevated oxidative stress was indicated by increased reactive oxygen species (ROS) and malondialdehyde (MDA) levels in the ob/ob group, while glutathione peroxidase 4 (GPX4) activity was significantly reduced. Ferrostatin-1 treatment decreases MDA levels and restores GPX4 activity. Additionally, ferrostatin mitigates iron overload and promotes macrophage polarization from M1 to M2, thereby reducing liver inflammation and fibrosis. Ferrostatin treatment reversed mitochondrial dysfunction in ob/ob mice. Our findings revealed that ferroptosis plays a significant role in the progression of obesity to hepatic steatosis and MASH. Inhibiting ferroptosis using ferrostatin-1 effectively improves liver histology, reduces oxidative stress, normalizes lipogenesis, and modulates macrophage polarization. This study highlights the potential of targeting ferroptosis as a therapeutic strategy for obesity-related liver diseases, warranting further investigation in clinical settings.


  • Open Access

    Ferroptosis in the Progression of Steatotic Liver Disease in Obese Mice: Implications of Its Inhibition

    by Gi Cheol Park, Soo-Young Bang, Ji Min Kim, Sung-Chan Shin, Yong-Il Cheon, Kwang Min Kim, Hanaro Park, Eui-Suk Sung, Minhyung Lee, Jin-Choon Lee, et al.

    Ferroptosis, a form of regulated cell death characterized by lipid peroxidation and iron accumulation, has been implicated in the progression of metabolic dysfunction-associated steatohepatitis (MASH) in obesity. This study investigated the role of ferroptosis in the development of hepatic steatosis and MASH in obese mice and assessed the therapeutic potential of ferrostatin-1, a ferroptosis inhibitor. C57BL/6J wild-type mice (n = 8) and ob/ob (n = 16) were maintained on a standard chow diet. Mice were divided into three groups that included C57BL/6 (n = 8), ob/ob (n = 8), and ob/ob + ferrostatin-1 (FER) (n = 8), with the latter group receiving an intraperitoneal injection of 5 μM/kg ferrostatin three times per week for eight weeks. Following treatment, serum and tissue samples were collected for analysis. Significant hepatic steatosis and increased lipogenesis markers were observed in ob/ob mice, and this was normalized in the ob/ob + FER group treated with ferrostatin-1. Elevated oxidative stress was indicated by increased reactive oxygen species (ROS) and Malondialdehyde (MDA) levels in the ob/ob group, while glutathione peroxidase 4 (GPX4) activity was significantly reduced. Ferrostatin-1 treatment decreases MDA levels and restores GPX4 activity. Additionally, ferrostatin mitigates iron overload and promotes macrophage polarization from M1 to M2, thereby reducing liver inflammation and fibrosis. Ferrostatin treatment reversed mitochondrial dysfunction in ob/ob mice Our findings revealed that ferroptosis plays a significant role in the progression of obesity to hepatic steatosis and MASH. Inhibiting ferroptosis using ferrostatin-1 effectively improves liver histology, reduces oxidative stress, normalizes lipogenesis, and modulates macrophage polarization. This study highlights the potential of targeting ferroptosis as a therapeutic strategy for obesity-related liver diseases, warranting further investigation in clinical settings.


  • Open Access

    Comparison of survival outcomes between de novo and recurrent stage IV gastric cancers: A retrospective cohort study

    by Jun Ho Ji, Kwang Min Kim, Byung Soo Kwan, Sung Kim, Yong Seok Kim, Seong Hee Choi, Mi Hyeon Jin, Boo Young Ha, Jinah Kim, Jeff Liang, et al.

    Purpose: This study analyzes the characteristics and prognosis of patients with de novo and recurrent metastatic gastric cancers.Methods: This retrospective study included 301 advanced, pathologically confirmed gastric cancer patients who received palliative chemotherapy between 2012 and 2022. The de novo cohort included patients who presented with distant metastasis at diagnosis, and the recurrent metastatic cohort was composed of patients with metastasis after curative gastrectomy. We analyzed prognostic association by Cox regression and compared survival time of both cohorts using the Kaplan-Meier survival analysis.Results: The study included 167 de novo and 112 recurrent patients. No differences were noted among the patients with de novo disease and recurrent metastatic disease concerning age, sex, Eastern Cooperative Oncology Group scores, primary cancer location, and pathologic features. Patients in the recurrent group versus the de novo group had a longer duration of chemotherapy (1.16±1.18 years vs. 0.85±0.84 years, P= 0.01) and lower mean body mass index (20.22±2.78 kg/m2 vs. 21.93±3.38 kg/m2, P< 0.001). The median overall survival in the de novo group was 11.6 versus 14.4 months in the recurrent group (P= 0.02).Conclusion: De novo and recurrent metastatic gastric cancer are characterized by distinct subpopulations. Advanced gastric cancer patients with recurrence have significantly better survival versus those in the de novo cohort. The differences between de novo and recurrent gastric cancer patient outcomes could facilitate discussions about the selection of the clinical trial of each patient and help with their personalized treatment.

  • Open Access

    Efficacy and Safety of Chemotherapy in Elderly Patients with Unresectable Pancreatic Cancer

    by Byung Soo Kwan, Ok Jae Lee, Hyun Jin Kim, Kwang Min Kim, Sang Goon Shim, Dae Hyeon Cho, Sung Min Kong, Jun Young Kim, Jun Ho Ji

    Background/Aims: The incidence of pancreatic cancer (PC) is gradually increasing among elderly individuals, but there are insufficient clinical data on elderly individuals. To determine the efficacy and safety of chemotherapy, we compared the. the outcomes of elderly patients with unresectable PC. Methods: We enrolled patients aged 75 years or older diagnosed with PC from 1 January 2010 to 30 November 2021. Propensity score matching (PSM) was used to reduce the heterogeneity of the study population. For efficacy evaluation, the median overall survival (OS) was estimated for the chemotherapy and nonchemotherapy groups. Chemotherapy tolerability evaluations were also investigated. Results: The study included 115 patients, 47 of whom received chemotherapy and 68 who did not. After PSM, compared with the nonchemotherapy group, the chemotherapy group had more myocardial infarctions (14.6 vs. 0.0%, p < 0.001) and chronic obstructive pulmonary disease (4.4 vs. 0.0%, p = 0.043). The primary endpoint, median OS, was significantly different in the with vs. without chemotherapy groups (203 vs. 106 days, p = 0.013). In the chemotherapy group, 10 patients (21.3%) discontinued treatment due to adverse events. However, there were no reports of death due to severe adverse events. Conclusions: This study demonstrated that chemotherapy improved median OS among elderly patients. These data could support the use of chemotherapy for elderly patients with unresectable PC.


  • Open Access

    Clinical Outcomes and Validation of Ursodeoxycholic Acid Response Scores in Patients with Korean Primary Biliary Cholangitis: A Multicenter Cohort Study

    by Jong-In Chang, Jung Hee Kim, Dong Hyun Sinn, Ju-Yeon Cho, Kwang Min Kim, Joo Hyun Oh, Yewan Park, Won Sohn, Myung Ji Goh, Wonseok Kang, et al.

    Jong-In Chang, Jung Hee Kim, Dong Hyun Sinn, Ju-Yeon Cho, Kwang Min Kim, Joo Hyun Oh, Yewan Park, Won Sohn, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, and Seung-Woon Paik. Gut and Liver 2023;17:620-8. https://doi.org/10.5009/gnl220420


  • Efficacy and safety of glecaprevir/pibrentasvir treatment in Koreans with chronic hepatitis C: A retrospective study

    by Byung Soo Kwan, Sung Min Kong, Sang Goon Shim, Kwang Min Kim, Gil Jong Yu, Jae Jin Lee, Jin Dong Kim